Rezolute, Inc.
NASDAQ:RZLTBiotechnology
+$0.30 today
- Market cap
- $411.10M
- Beta
- 0.65
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.78
Volume 2.93M
Average 2.03M
RZLT Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Rezolute, Inc.NASDAQ: RZLT
Accounts Payables · Q3 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q3 FY2026 accounts payables was -$587K, compared with $3.35M a year earlier. Trailing-twelve-month accounts payables was -$3.31M.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near -$587K or moves back toward the trailing-twelve-month quarterly average of -$827K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 1.42M USD
- Year-over-year change
- +31.2%
- 4-year CAGR
- +77.9%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 1.42M | +31.2% |
| FY2024 | 2024-06-30 | 1.08M | -49.3% |
| FY2023 | 2023-06-30 | 2.14M | +19518.2% |
| FY2022 | 2022-06-30 | (11K) | -107.7% |
| FY2021 | 2021-06-30 | 142K | — |
Accounts Payables vs competitors
How RZLT compares with its peers on the latest reported figures
- RZLT's LTM Mar 2026 accounts payables of $3.31M is the 4th largest of the 5 companies compared; the peer median is $8M.
- Its year-over-year change of -210.1% is the lowest of 5, against a peer median of +157.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.14M | +61.6% | — | 6.0% | |
| LTM Mar 2026 | $15.45M | +166.8% | -33.0% | 2.3% | |
| LTM Mar 2026 | $8.85M | +148.8% | — | 7.2% | |
| LTM Mar 2026 | $3.31M | -210.1% | — | — | |
| LTM Mar 2026 | $540K | +871.4% | — | 62.9% | |
| Peer median (excluding RZLT) | $8M | +157.8% | -33.0% | 6.6% | |
Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Depreciation & Amortization | 13K | 13K | 30K | 36K | 31K |
| Deferred Income Tax | (1.78M) | 0 | (1.37M) | 0 | 0 |
| Stock-Based Compensation | 3.97M | 3.69M | 7.27M | 7.36M | 7.12M |
| Change in Working Capital | (2.12M) | (642K) | 1.02M | 3.1M | 47K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 142K | (11K) | 2.14M | 1.08M | 1.42M |
| Other Working Capital | (2.26M) | (631K) | (1.12M) | 2.02M | (1.37M) |
| Other Non-Cash Items | 384K | (1.61M) | 352K | 595K | (1.86M) |
| Operating Cash Flow | (20.44M) | (39.62M) | (44.48M) | (57.37M) | (69.08M) |
| Capital Expenditures | 0 | 0 | (153K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 101.46M | 0 | 0 |
| Purchases of Investments | 0 | 0 | (107.31M) | (66.4M) | (128.14M) |
| Sales of Investments | 0 | 0 | 6M | 115.1M | 113.6M |
| Other Investing Activities | 0 | 0 | (101.46M) | 0 | 0 |
| Investing Cash Flow | 0 | 0 | (101.46M) | 48.7M | (14.54M) |
| Debt Repayment | 15M | (16.01M) | 0 | 0 | 0 |
| Common Stock Issued | 41M | 122.82M | 12.33M | 49.02M | 107.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (4.47M) | 31.39M | (759K) | 14.01M | 0 |
| Financing Cash Flow | 51.53M | 148.98M | 11.57M | 63.03M | 107.33M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 31.09M | 109.36M | (134.37M) | 54.36M | 23.71M |
| Free Cash Flow | (20.44M) | (39.62M) | (44.63M) | (57.37M) | (69.08M) |
Rezolute, Inc.
NASDAQ:RZLT
Intrinsic Alpha fair value
Locked
Current Price
$4.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.